This is a critical problem, especially because PCa detected in AAs is typically more aggressive and advanced compared to PCa in CAs, and the mortality rate for AAs with PCa compared to CAs is significantly higher, even after adjusting for prognostic factors (PSA level, age, clinical stage, and Gleason score) [10,11]. This evidence concerns the gene KLK3 and posterior cortical atrophy.